Magle Chemoswed Holding AB (publ) ("Magle Group" or the "Company") announces that it has completed the restructuring of its outstanding debt and capital structure (the "Restructuring") as previously announced on 10 July 2026. All implementation steps have been finalised, including the issuance of super senior bonds, the structural write-down and cancellation of the existing bonds, the issuance of reinstated bonds, the directed set-off issue to bondholders and the directed share issues to investors.
The Restructuring comprised the issuance of super senior bonds with a total nominal amount of up to approximately SEK 203 million, a debt-for-equity swap whereby part of the Company's initial bonds were written down and cancelled with the holders receiving new shares, the restatement of remaining bond debt as reinstated bonds, and directed share issues to existing shareholders and board members.
Aaron Wong, CEO, comments:
"With the Restructuring now completed, we have strengthened Magle Group's balance sheet, reduced the Company's indebtedness and created a firm foundation to focus on the operational turnaround of the business."
Contacts
Aaron Wong, CEO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com
About Us
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed - a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com
Redeye Nordic Growth AB is the company's Certified Adviser.
